title: Epithelium-off versus transepithelial corneal collagen crosslinking for progressive corneal ectasia: a randomised and controlled trial.
abstract: To compare the outcomes of corneal collagen crosslinking (CXL) for the treatment of progressive corneal ectasia using a standard epithelium-off technique versus a transepithelial technique with enhanced riboflavin solution.
  
  
  
  One hundred and forty-four eyes with progressive corneal ectasia were prospectively randomised into a transepithelial CXL study arm or an epithelium-off CXL control arm. Follow-up examinations were set at 3, 6, 12 and 24 months. The primary outcome measure was change in the maximum simulated keratometry value (Ksteep) after 24 months of follow-up. The secondary outcome measure was change in the best spectacle-corrected visual acuity (BSCVA) after 24 months follow-up.
  
  
  
  One hundred and thirty-one eyes completed the 24-month follow-up interval. Change in Ksteepwas -1.52±0.66 dioptres (D) for the control group versus -0.54±0.58 D for the study group at 24 months of follow-up (p=0.0320). Change in BSCVA was -0.18±0.09 logMAR for the control group versus -0.14±0.08 logMAR for the study group at 24 months of follow-up (p=0.4978). Two eyes in the control group had minor postoperative complications that did not affect the final visual acuity, and one eye in the control group underwent keratoplasty during the study interval.
  
  
  
  At 24 months of follow-up, subjects in the epithelium-off CXL group demonstrated a greater improvement in Ksteepcompared with subjects in the transepithelial CXL group, but no statistically significant difference in BSCVA was found between groups.
  
  
  
  NCT01708538; pre-results.
authors.affiliation: Panhandle Eye Group, Amarillo, Texas, USA.|Texas Tech University Health Science Center, Amarillo, Texas, USA.
authors.forename: Sloan W
authors.initials: SW
authors.lastname: Rush
authors.affiliation: Panhandle Eye Group, Amarillo, Texas, USA.|Texas Tech University Health Science Center, Amarillo, Texas, USA.|Southwest Retina Specialists, Amarillo, Texas, USA.
authors.forename: Ryan B
authors.initials: RB
authors.lastname: Rush
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003094:Collagen / Q000378:metabolism; D003315:Cornea / Q000473:pathology*; D003316:Corneal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004108:Dilatation, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004728:Endothelium, Corneal / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D012256:Riboflavin / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin
keywords: Cornea